News &amp; Updates

PF-06826647, a novel tyrosine kinase 2 inhibitor in development, outperforms placebo at reducing disease severity in patient with moderate-to-severe plaque psoriasis, reveals a new trial.

New oral tyrosine kinase 2 inhibitor shows promise against moderate-to-severe plaque psoriasis

23 Apr 2022

Circulating antioxidants play no protective role in breast, ovarian cancers

Genetically predicted circulating antioxidants do not appear to have a protective effect on the risk of breast cancer, ovarian cancer, or their histotypes, according to the results of a two-sample Mendelian randomization study.

Circulating antioxidants play no protective role in breast, ovarian cancers

23 Apr 2022

Most children suffer from vitamin D deficiency

Levels of 25-hydroxyvitamin D (25(OH)D) are deficient or insufficient in most children, reports a recent study. Aside from vitamin D intake, time spent outdoors and higher exposure to UV radiation seem to be effective methods of improving 25(OH)D status.

Most children suffer from vitamin D deficiency

Furmonertinib emerges as potential first-line option for EGFRm NSCLC

Treatment-naïve patients with locally advanced or metastatic EGFR-mutated (EGFRm) non-small-cell lung cancer (NSCLC) experience improved progression-free survival (PFS) when treated with furmonertinib compared with gefitinib, according to results of the phase III FURLONG study.

Furmonertinib emerges as potential first-line option for EGFRm NSCLC

22 Apr 2022

Ritlecitinib, brepocitinib show promise against scalp alopecia areata

Ritlecitinib and brepocitinib lead to improvements in scalp alopecia areata and its associated biomarkers, reveals a recent substudy of a phase 2a trial.

Ritlecitinib, brepocitinib show promise against scalp alopecia areata

22 Apr 2022

Finerenone reduces CV events, renal outcomes in T2D-related CKD

A pooled analysis of 13,171 patients from both the FIDELIO-DKD and FIGARO-DKD trials has confirmed the beneficial effects of finerenone, according to results of FIDELITY study, presented at the recently concluded American College of Cardiology Annual Scientific Session (ACC 2022).

Finerenone reduces CV events, renal outcomes in T2D-related CKD

Can we predict sudden cardiac arrests in the general population?

The quest for a personalized risk model that can foretell sudden cardiac arrests (SCAs) in the general population remains, as the ESCAPE-NET* research project falls short in their pursuit to identify such a model that can predict SCA risk in this population.

Can we predict sudden cardiac arrests in the general population?

Larger tumours tied to prostate cancer biochemical recurrence

In patients with localized prostate cancer (PCa), higher tumour volume (TV) appears to cut biochemical recurrence-free survival short, a recent study has found.

Larger tumours tied to prostate cancer biochemical recurrence

22 Apr 2022

Increased intake of dietary cholesterol, eggs detrimental to heart

Consuming dietary cholesterol and eggs in high amounts contributes to an increased risk of overall and cardiovascular disease mortality, according to a large study.

Increased intake of dietary cholesterol, eggs detrimental to heart

Mitapivat increases Hb levels in patients with pyruvate kinase deficiency

The use of mitapivat increased haemoglobin (Hb) levels in patients with pyruvate kinase deficiency (PKD) who did not receive any regular blood transfusions, according to the ACTIVATE* study.

Mitapivat increases Hb levels in patients with pyruvate kinase deficiency